Abstract
Multiple targeted therapies have been shown to extend overall survival among men with metastatic castrate resistant prostate cancer including androgen axis modulators, PARP inhibitors, and PSMA theranostics. These and other treatments are being trialed in earlier disease states including in clinically localized prostate cancer. When moved earlier in disease course, therapeutic index and drug effect become more salient. As these therapies are molecularly based, patient subgroups with superior oncological responses might be defined by genomic signatures of their cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
